Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement to acquire B.R.A.H.M.S. AG for €330 million (approximately $470 million USD). B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

From Thermo Fisher Scientific Inc. 3 Sep 2009

Boron-based molecules can be used as new pharmacophores

Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies.

3 Sep 2009

Alloantigen-specific Treg cells targeted for organ transplantation

An increased understanding of the role of the body's immune system in the development of diseases such as prostate cancer, squamous cell carcinoma (a type of skin cancer), type 1 diabetes, autoimmune liver disease, and in the rejection of transplanted organs by some transplant patients, has paved the way for a pioneering research programme which aims to develop 'enhanced' cells as therapies.

3 Sep 2009

Bretford pioneers antimicrobial finishes on tables and carts

Bretford Manufacturing, Inc., manufacturer of dependable furniture products that improve how people work and learn, is the first to offer multi-surface antimicrobial finishes on more than 50 different tables and carts for learning and training environments.

2 Sep 2009

Selexis SA and NKT Therapeutics sign research services agreement

Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM).

2 Sep 2009

Alpha Pro Tech to triple N-95 respirator mask production

Alpha Pro Tech, Ltd. (NYSE Amex: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that it will be tripling the average output of N-95 respirator masks that it has been producing since May, which will help accommodate Alpha Pro Tech’s current backlog and increase availability for the upcoming flu season/swine flu season.

2 Sep 2009

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

LTS LOHMANN Therapie-Systeme AG, the leading developer and manufacturer of transdermal, topical and oral systems with facilities in Andernach, Germany and West Caldwell, New Jersey, celebrates its 25th anniversary.

1 Sep 2009

Clinical Healthcare Enterprise Framework to help healthcare HR for effective talent management

Salary.com, Inc. (NASDAQ: SLRY), a leading provider of on-demand compensation, payroll and talent management solutions, announced today that it has added the Clinical Healthcare Enterprise Framework to its growing Job Model and Competency Library of more than 1,200 job models and 1,300 functional competencies, which provide data and structure for typical jobs at all levels of an organization. The framework will enable healthcare HR professionals to create job roles easily, deliver job models quickly, and power their talent management systems.

1 Sep 2009

New Vice President for Bioanalytical Development lab appointed by Cytovance Biologics

Cytovance Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the addition of Dr. Jeffrey Su as Vice President of Bioanalytical Development to its diverse and growing scientific staff. Dr. Su will head up the state of the art Bioanalytical Development laboratory supporting existing and new client needs.

1 Sep 2009

Stanford University starts recruiting participants for swine flu vaccine clinical trial

The Stanford University School of Medicine is recruiting participants for a clinical trial to determine the safety of an experimental vaccine against the new H1N1 strain of influenza when the vaccine is combined with an immune-stimulating substance called an adjuvant. The trial will also examine whether use of the adjuvant improves the immune response to the vaccine.

31 Aug 2009

Merck undergoes restructuring after Schering-Plough merger

Richard T. Clark, chairman, president and chief executive officer of Merck & Co., Inc. (NYSE: MRK) today announced a new organizational structure and named top management and senior leaders for the new Merck effective upon completion of the merger of Merck & Co., Inc. and Schering-Plough Corporation. Mr. Clark was named CEO of the combined company when the merger agreement was signed in March.

31 Aug 2009

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.

31 Aug 2009

BloodStor biopreservation media product platform for cord blood banking industry

BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced the launch of its BloodStor biopreservation media product platform.

31 Aug 2009

Ranaz Corporation to raise funds through private placement

Ranaz Corporation ("Ranaz") (TSXV: RNZ), a company specialized in the manufacturing and marketing of protein and dietary supplements, announces that it intends to raise $675,000 through a non-brokered private placement of units.

29 Aug 2009

Ranaz reports second quarter 2009 financial results

Ranaz Corporation ("Ranaz"), a company specialized in the manufacturing and marketing of protein and dietary supplements, reported its results today for the second quarter ended June 30, 2009.

29 Aug 2009

Covalon Technologies announces fiscal 2009 third-quarter results

Covalon Technologies Ltd. (TSX VENTURE:COV) announces the release of its financial statements for the third quarter of fiscal 2009 ending June 30, 2009. Revenues from product sales, coating services and licensing fees for the three months ended June 30, 2009 were $401,837, an increase of $64,575 over the same period in the previous year.

28 Aug 2009

Sinovac to supply its Anflu seasonal flu vaccine to the Beijing Public Health Bureau

Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu(R), Sinovac's seasonal influenza vaccine, for the benefit of the citizens of Beijing. The Beijing Public Health Bureau completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26, 2009. The agreement will be executed after the public notice period.

28 Aug 2009

Bavarian Nordic generates a revenue of DKK 33 million in the first half of 2009

In the first half of 2009 Bavarian Nordic generated revenue of DKK 33 million and recorded a loss before tax of DKK 188 million. As of 30 June 2009 the Group's net free liquidity was DKK 489 million.

28 Aug 2009

Kamada finalizes agreement for the distribution of its intravenous alpha-1 antitrypsin in the United States

Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has entered into an exclusive agreement with a large US specialty pharmaceutical distributor company for the distribution of its flagship product, intravenous alpha-1 antitrypsin (AAT-IV) in the United States.

28 Aug 2009

Copan Diagnostics to expand manufacturing operations at its Murrieta facility

Despite tough economic times, Copan is proud to announce the expansion of its US operations. Copan Diagnostics, Inc. is undertaking a new multimillion dollar investment project to bring plastic transfer pipet and additional medical device manufacturing operations to its facility in Murrieta, California.

28 Aug 2009